Kornimate/medical-research-clean huggingface dataset:
predicting response patterns to treatment in glioblastoma (gbm) patients

Conditions: Glioblastoma

Summary: prophetic gbm - predicting response patterns to treatment in glioblastoma (gbm) oncology patients based on host response evaluation during anti-cancer treatments

the goal of this research study is identify new host response proteins, pathways and mechanisms that are associated with responsiveness to gbm treatment modalities. this will serve as a tool for physicians when making treatment decisions. the investigators also aim to identify the metabolic pathways that could lead to better therapeutic options. the patients will be given their treatment according to the institute's standard of care. the patients will provide up to 5 blood samples and clinical data will be collected from their medical records. the data obtained from the blood samples and the medical records of the patients will be used to search for potential mechanisms that are involved in response to treatment, and to identify potential targets to increase the response, and hence, increase treatment effectiveness or suggest potential new treatments.

Eligibility criteria:
inclusion criteria: 1. provision of informed consent prior to any study-specific procedures. 2. male or female aged at least 18 years. 3. kps not less than 50. 4. normal hematologic, renal and liver function: 1. absolute neutrophil count above 1500/mm3, platelets above 100,000/mm3, hemoglobin above 9 g/dl; 2. creatinine concentration not more than 1.4 mg/dl, or creatinine clearance above 40 ml/min; 3. total bilirubin below 1.5 mg/dl, alt+ ast levels not more than 3 times above the upper normal limit. 5. patients planned to receive standard of care tmz+rt treatment; ttf therapy during rt is permitted. exclusion criteria: 1. any concurrent and/or other active malignancy that has required systemic treatment within 2 years of surgery. except for basal cell carcinomas and squamous cell carcinomas that have been completely excised and considered cured at least 12 months prior to screening, and carcinoma in situ of the cervix that have been completely excised and cured at least 5 years prior to screening. 2. participation in another clinical trial which includes an investigational drug. 3. generalized impairment or mental incompetence that would render the patient unable to understand his/her participation in the study. 4. pregnancy.
a study to investigate the effect of ono-8539 on acid-induced oesophageal hypersensitivity in healthy volunteers

Conditions: Acid Reflux

Summary: a study to investigate the efficacy of ono-8539 on acid-induced oesophageal hypersensitivity in healthy male adult volunteers.

this is a randomised, double-blind, placebo-controlled, two-period crossover study, to investigate the efficacy of ono-8539 on acid-induced oesophageal hypersensitivity in healthy male adult volunteers. each subject will be randomised to ono-8539 or placebo twice daily in the first treatment period and the alternate treatment in the second treatment period. dosing in each period will be for 15 days.

Eligibility criteria:
inclusion criteria: * healthy caucasian male subjects, aged 18-45 years inclusive, will be entered into this study. exclusion criteria: * subjects will be excluded if they have a motility disorder, are not able to tolerate study procedures or have had gi surgery or have a condition that would affect the study results.
treatment of t1n0 invasive breast carcinoma by local excision implant

Conditions: Breast Cancer

Summary: the purpose of this study is to evaluate radiation therapy directed to a small region of the breast in women who were recently diagnosed with early stage invasive breast cancer.

* when participants undergo surgery to remove the tumor (lumpectomy), it will be followed by the placement of small flexible tubes throughout the region surrounding the site of operation. these tubes will remain in place for 7-9 days following the surgery. * the first 2-3 days, the tubes will not contain radioactivity. this time is used to do all the calculations necessary for treatment and to check the findings in the breast tissue that was removed. after 2-3 days, the tubes will be filled with a radioactive wire which will remain in place for the next 5 days. during this period of time, participants will be required to remain within the hospital. at the end of these 5 days, the radioactive wires and tubes will be removed.

Eligibility criteria:
inclusion criteria: * low risk of multifocal disease within the breast whose tumor location is favorable for brachytherapy catheter placement * diagnosis of invasive breast carcinoma (biopsy or fine needle aspiration cytology) and be clinical stage t1n0 (primary tumor \< 2cm, clinically negative nodes) * location of primary tumor is not immediately adjacent to the nipple of chest wall * no evidence of two or more separate tumors within the breast * all histologic types and pathologic grades of primary tumor * no extensive intraductal component (substantial intraductal carcinoma away from the primary tumor location) * no lymphatic or vascular invasion * lymph node staging by sentinel node excision or axillary dissection confirms node negative status (if node positive, implant is used to deliver boost to tumor bed) * assessment of final surgical margins should be predominantly negative, but a single small region of focal positivity is allowable as it is for whole breast radiation * 18 years of age or older exclusion criteria: * tumor is too close to the chest wall to allow placement of catheters * contraindications to radiation therapy are present, including a history of scleroderma, systemic lupus or other active connective tissue disease, pregnancy, or prior chest wall radiation

Keywords: early stage invasive breast cancer partial breast irradiation interstitial implant
intermittent and daily dosing for episodic (periodic) asthma (0476-302)(completed)

Conditions: Asthma

Summary: this is a year-long study evaluating the efficacy of both daily and intermittent treatment of asthma in children who experience symptoms episodically (i.e., seasonally, usually in the context of upper respiratory tract infection).


Eligibility criteria:
inclusion criteria: * patients aged 6 months to 5 years with episodic (periodic) asthma exclusion criteria: * patients who are not in otherwise good health * patients who have persistent asthma (continual asthma symptoms)
a comparison study of the tensile strength of sutures used in dermatologic surgery on the day of suture removal, following wound care with two different products

Conditions: Sutured Wounds

Summary: sutures are an integral part of surgery and available materials are diverse, as are the options for post-procedure care. both saline and hydrogen peroxide are commonly used cleansing agents. this study aims to compare the effect of saline and hydrogen peroxide on the tensile strength of 4-0 nylon sutures following removal from a cutaneous surgical wound.


Eligibility criteria:
inclusion criteria: * subject is willing to comply with the informed consent procedures * subject's wound is on the body or scalp * subject will be able to come to the clinic for suture removal on day 14 exclusion criteria: * subject is less than 18 years of age * subject's wound was not closed with 4-0 nylon sutures * subject's wound is on the face * subject plans to apply other topicals to the area under study * subject's suture is removed before or after day 14

Keywords: suture, tensile strength, wound care, saline, hydrogen peroxide, skin closure, wounds, wound healing, wound cleansing, antiseptics
oxygen monitoring of patients after surgery on the hospital general care floor

Conditions: Sleep Disordered Breathing

Summary: the pain medication given after major surgery may cause some patients to stop breathing for periods of time especially at night time. an oxygen monitor may reflect this abnormal breathing pattern. this is an observational study of 100 post-operative patients who will be monitored with a pulse oximeter for a minimum of two nights and a maximum of five nights to determine the prevalence of this abnormal breathing pattern.

no further details necessary or available.

Eligibility criteria:
inclusion criteria: * age of 18 years or older * discharge from the post-anesthesia care unit (pacu) to the gcf after any of the following major surgeries: bariatric surgery, major orthopedic surgery (e.g., total hip replacement), major general surgery (e.g., bowel resections, open cholecystectomy), and major gynecological surgery (e.g., radical hysterectomy) exclusion criteria: * pre-existing central neurological disease, including but not limited to recent traumatic brain injury, stroke, and neurodegenerative disease * ongoing use of mechanical ventilation or continuous positive airway pressure in the gcf

Keywords: post op patients continuous pulse oximetry monitoring major surgery
the effect of oxygen exposure during newborn resuscitation on lung injury

Conditions: Prematurity; Oxidative Pulmonary Injury

Summary: hypothesis: in this feasibility study, hyperoxemia, as approximated by transcutaneous hemoglobin saturation with oxygen (sp02), at the time of birth will cause sustained pulmonary oxidative stress as demonstrated by elevation of pulmonary protein carbonyl. furthermore, this oxidative stress will be directly proportional to the imposed oxygen-burden during resuscitation at the time of birth. this study will give us information regarding the magnitude of protein carbonyl elevation in the preterm infant. with these results we will be able to 1. establish the technique for the running or protein carbonyl assays and 2. calculate an appropriate sample size for a future randomized control trial.

immediately prior to birth, preterm infants (\<= 32 weeks gestation) will be randomized to one of three groups: 1. low oxygen burden (lob) - initiation of resuscitation with 21% 02, ii. moderate oxygen burden (mob) - initiation of resuscitation with 100% 02 and iii. high oxygen burden (hob) - 100% 02 used for the entire resuscitation. a pulse oximetry monitor will be connected to a probe on the infant's hand to measure the transcutaneous hemoglobin saturation with oxygen (sp02). adjustments to the inspired oxygen concentration will be made every 15 seconds for infants in the lob and mob groups to achieve a target sp02 range of 85-92%. resuscitation will otherwise proceed as per standard of care. the intervention will end upon arrival in the neonatal intensive care unit.

Eligibility criteria:
inclusion criteria: * \<=32 weeks gestation * inborn * require intubation exclusion criteria: * lethal anomalies * cyanotic congenital heart disease * known hemoglobinopathy * risk factors for persistent pulmonary hypertension

Keywords: newborn preterm resuscitation oxidative injury protein carbonyl
l-arginine treatment for severe vascular fetal intrauterine growth restriction: a randomized double bind controlled trial (l arginine in iugr)

Conditions: Intra Uterine Growth Retardation

Summary: although there is a strong rationale to supplement gravid patients suffering intrauterine growth restriction (iugr) or preeclampsia with arginine or other nitric oxide donors, evidence in the literature has been inconclusive. the current study was designed to determine whether oral treatment with l-arginine, a nitric oxide (no) donor, would enhance birth weight and/or decrease neonatal morbidity in pregnancies with severe vascular intrauterine growth restriction (iugr).

patients and methods: 44 patients with a singleton pregnancy who had been referred for iugr detected by ultrasonic examination were included. vascular iugr was defined by fetal abdominal circumference less than or equal to the third percentile, associated with abnormal uterine doppler. after double blind randomization, patients received either 14 g/day of l-arginine (90 ml syrup, veyron france laboratories), or a placebo. doppler ultrasound examination of the uterine, umbilical and cerebral circulation, and of ductus venosus was performed prior to inclusion, after 7 days of treatment, and the day before delivery. ultrasound examination was performed upon randomization, and weekly until birth. venous blood and urine samples were collected before initiation and after 7 days of treatment, and both maternal and umbilical venous samples were obtained at delivery for nitrate and nitrite (no2-/ no3-) determination.

Eligibility criteria:
inclusion criteria: * multicenter randomized trial. * patients with a singleton pregnancy with iugr defined by fetal abdominal circumference less than or equal to the third percentile for gestational age, and abnormal uterine doppler. uterine doppler was considered pathologic if pourcelot's resistance index (s-d/s) was equal to or higher than 0.7, and/or if an obvious notch was present. if the placenta was not median, the side of the pathologic doppler had to be on the same side as the placenta exclusion criteria: * acute fetal distress * non vascular and non severe iugr (normal uterine doppler scans and/or abdominal circumference \> 3rd percentile) * maternal immune disorder * iugr from an infectious etiology * iugr associated with fetal malformation, multifetal pregnancy, and preeclampsia upon inclusion

Keywords: severe intra uterine growth retardation below the third centile with abnormal uterine doppler severe growth retardation with pathologic uterine doppler l-arginine nitric oxide donor
population research of sublingual microcirculation data of patients with systemic diseases

Conditions: Hypertension; Diabetes Mellitus

Summary: this is an observational clinical study, patients with systemic diseases will be enrolled according to the inclusion and exclusion criteria. patients will received the examination of sublingual microcirculation by using incident dark field video microscope (cytocam，braedius battery powered transilluminator). the microcirculation data includes total small vessel density, perfused small vessel density, microvascular flow index, and heterogeneity index. the patients will be divided into right groups according to their systemic diseases as follows: group 1 hypertension (60 patients), group 2 diabetes mellitus (60), group 3 hypertension and diabetes mellitus (60), group 4 end stage renal disease with hemodialysis (60), group 5 kidney transplant recipients (60), group 6 coronary artery disease (60), and group 7 peripheral arterial occlusive disease (60).


Eligibility criteria:
inclusion criteria: * patients aged from 20 to 79 years old * bmi ranged from 18.5 to 27 kg/m2 * presence of one of the condition * diagnosed hypertension \> 6 months, without other systemic diseases * diagnosed diabetes mellitus \> 6 months, without other systemic diseases * diagnosed with both hypertension and diabetes mellitus \> 6 months, without other systemic diseases * diagnosed with end stage renal disease \> 6 months * received renal replacement therapy \> 6 months * diagnosed with coronary artery disease \> 6 months * diagnosed with peripheral arterial occlusive diseases \> 6 months exclusion criteria: * diagnosed with sepsis, major trauma, or admission to icu within one month * body temperature higher than 37.5 ℃ or lower than 35.5 ℃ * any on of the following condition * asthma * chronic obstructive pulmonary disease * endocrine diseases * hematological disorders * uncured cancer * chronic uncured infection * other major disease with limited daily activity * non-native speakers
evaluation of uterine fibroids by ceus and shape pre and post uae

Conditions: Uterine Fibroid

Summary: this study goals are to determine the patterns of uterine fibroid vascularity pre and post uae using ceus resulting in an alternative to gadolinium-enhanced mri that is less expensive, has less contra-indications and side effects, is real time, and noninvasive helping physicians to evaluate the result of uae procedures. also, this study will evaluate uterine fibroid pressures using shape, comparing the results with normal myometrium tissue in order to determine its characteristics and tissue differences, which we believe will lead to the development of a new biomarker for the diagnosis and treatment of uterine fibroids.


Eligibility criteria:
inclusion criteria: * be a female diagnosed with endometrial cancer and scheduled for uae. * be over the age of 18 years. * if the subject is of child-bearing potential, must have a negative pregnancy test. * be conscious and able to comply with study procedures. * have read and signed the irb approved consent form for participating in the study. exclusion criteria: * females who are pregnant or nursing. * patients who have received an investigational drug in the 30 days before study drug administration, or will receive one within 72 hours afterwards. * patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable. for example: * patients on life support or in a critical care unit. * patients with clinically unstable cardiac arrhythmias, such as recurrent ventricular tachycardia. * patients with recent cerebral hemorrhage. * patients who have undergone surgery within 24 hours prior to the study sonographic examination. * patients with congenital heart defects. * patient with a known allergy to definity.
alzheimer's disease and physiological, cognitive function and bdnf levels of plasma adaptation after exercise training

Conditions: Alzheimer's Disease

Summary: alzheimer's disease (ad) is a neurodegenerative disease leading to one of the most common forms of dementia in humans and memory disorder is one of the first symptoms that lead to diagnosis.

present in greater amounts in the regions of the hippocampus and cortex, the brain-derived neurotrophic factor (bdnf) is essential to both learning and memory processes. this protein is found in lower amounts in people with ad. acute physical activity of moderate to vigorous intensity would increase the levels of plasma bdnf whether for a healthy person or a person with ad. nevertheless in rest, healthy people have higher level of bdnf than individuals with ad. there are no studies on the effect of chronic exercise based on bdnf level at rest in people with ad. in a hypothetical endurance training of 18 sessions, whether interval or continuous training the levels of bdnf would increase in people with ad at rest. their physiological and neuropsychological performances would also show a rise.

Eligibility criteria:
inclusion criteria: * alzheimer's disease patients diagnosed by a consultation memory (dsm- iv) * person with at least 60 years * person with a score higher than 15 in the mini mental state examination * no one can achieve the pedaling motion * people who do not perform regular physical activity on bike * nobody has given free and informed consent in writing or obtained from a trusted person or the family environment * people affiliated to a social security exclusion criteria: * patient who refused to provide written consent * inability to pedal * recent myocardial necrosis (less than 3 months) * aortic stenosis * uncompensated heart failure * unstable angina * ventricular arrythmia * pulmonary embolism * coxarthrosis, knee, ankle osteoarthritis * not affiliated to a social security * patient already participating in another biomedical research

Keywords: endurance training bdnf analysis cognitive function physiological abilities
investigating facilitator-driven, multi-level implementation strategies in federally qualified health centers to improve provider recommendation and hpv vaccination rates among latino/a adolescents

Conditions: Human Papillomavirus Infection

Summary: the purpose of this study is to determine the provider- and practice-level characteristics that influence the impact of implementation strategies guided by practice facilitation in each clinical practice, to test whether the facilitator-driven provider- and practice-level implementation strategies increase provider recommendations and human papilloma virus (hpv) vaccination rates and to evaluate implementation and future sustainability of the facilitator-driven implementation strategies across nine clinical practice sites


Eligibility criteria:
inclusion criteria: * fqhc's with less than 60% hpv vaccine initiation rate for 11-12 year old adolescents overall at their practice sites * fqhc's that have family medicine and/or pediatric practices * a total adolescent patient population at least 50% latino * be willing for health care provider (hcp) and staff members to receive education, training, and support; complete standardized measurement, and agree to randomization. * providers, aged 18 and over, employed at each fqhc (4 staff per practice) * staff, aged 18 and over, employed at each fqhc (5 staff per practice) * implementation team members (i.e., administrative designee, health care providers, immunization navigators, and other staff), aged 18 and over, employed at each fqhc (4 members per practice) * parents (aged 18 and over) of patients ages 11-17 seeking care at each fqhc (25 per practice). exclusion criteria: -fqhcs that participated in the pilot study were excluded.

Keywords: hpv vaccination
a study to evaluate the efficacy and safety of risperidone (r064766) in children and adolescents with irritability associated with autistic disorder

Conditions: Autistic Disorder in Children and Adolescents

Summary: the purpose of this study is to evaluate the efficacy of risperidone compared with placebo in children and adolescents with irritability associated with autistic disorder.

this is a randomized (the drug is assigned by chance), 8-week, double-blind (neither physician nor patient knows the treatment that the patient receives), placebo-controlled (placebo is an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial), parallel-group (each group of patients will be treated at the same time), flexible-dose, multicenter study. it will be followed by a 48-week, flexible-dose, open-label (all people know the identity of the intervention) extension, to evaluate the efficacy and safety of risperidone in children and adolescents with a diagnosis of autistic disorder (severe form of pervasive developmental disorder) who have associated irritability. the study consists of up to 2-week screening phase, an 8-week double-blind phase, a 48-week open-label phase, and a 1-week follow-up phase.

Eligibility criteria:
inclusion criteria: * diagnostic for autistic disorder * a clinical global impression - severity (cgi-s) score of =\>4 and an aberrant behavior checklist - japanese version (abc-j) irritability subscale score of =\>18 * patients with mental age of \>18 months as measured by appropriate developmental or mental scales * patients who have an appropriate caregiver, eg, parent or study-site personnel, who is able to observe the patient's condition, provide information, and evaluate the patient's response appropriately exclusion criteria: * patients with previous or current psychotic disorder (eg, schizophrenia, bipolar disorder, or other psychiatric disorders) or with pervasive developmental disorder not otherwise specified, asperger's disorder, rett's disorder, pediatric destructive behavior disorder, or substance dependence * patients with a clinically significant endocrine, metabolic, cardiac, hepatic, renal, or pulmonary disorder, or hypertension * weight of \<15 kg at the time of screening and baseline * patients with qtc\>450 msec in the standard 12-lead electrocardiogram (ecg) at the time of screening * patients with known hypersensitivity to risperidone or paliperidone

Keywords: autistic disorder in children and adolescents risperidone (r064766) children adolescents irritability autistic disorder